This group identifies and ascertains the effectiveness of both the operating characteristics and the impacts on mortality, and immediate and downstream risks of molecular and imaging cancer detection technologies and practices. It systematically assesses the value of cancer screening and early detection tests and technologies by establishing their ability to reduce cancer mortality.
This is a listing of Requests for Applications (RFA), Program Announcements (PA), and Notices specific to the group's key programs.
The group conducts these large prevention trials: Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, National Lung Screening Trial (NLST), and International Prostate Screening Trials Evaluation Group (IPSTEG).
This section contains links to PLCO-related publications.
Mission, staff list, and contact information are in this section.
Back to top
